News 24 Jun. 2021
Curtis successfully defends foreign states' procedural privileges in the UK Supreme Court
News 23 Jun. 2021
Ibrahim Elsadig joins Curtis as Partner in Dubai
News 09 Aug. 2021
Curtis, Mallet-Prevost, Colt & Mosle enters into association with Chevalier Law in Singapore.
Event 23 Apr. 2021
Partner Borzu Sabahi to speak on Damages, Enforcement and Annulment of Arbitral Awards at Executive Training Program hosted by the Government of India and the Indian Institute of Foreign Trade
Event 07 Sep. 2021
Simon Batifort and Andrew Larkin Speak at the European Society of International Law’s 2021 Annual Conference
Client Alert 06 Sep. 2021
Disclosure of Beneficial Ownership in 2021 – Luxembourg Perspectives – Alert 5 of the Series
Partner Elisa Botero Speaks on Panel within Framework of Colombia's 4th National Arbitration Competition
News 30 Aug. 2021
Curtis Returns to SCOTUS in Historic Sequel on the Rights of Citizens in Puerto Rico
News 16 Aug. 2021
Curtis Establishes Presence in Saudi Arabia
News 26 Jul. 2021
Curtis' Private Client Group and Attorneys Recognized in the 2021 Chambers High-Net-Worth Guide.
Client Alert 24 Jun. 2021
U.S. Insight: Update on Virtual Notarization (Executive Order 202.7) During the COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021)
U.S. Insight: Update on Virtual Witnessing (New York Executive Order 202.14) During The COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021)
Companies operating in the pharmaceutical and related sectors such as healthcare must grapple with cutting-edge scientific development as well as shifting regulatory regimes, which complicate corporate mergers and acquisitions, managing intellectual property portfolios and patents, and litigating disputes. The ethical dimension makes it imperative to have the right legal advice.
Curtis provides a wide range of legal services to clients in the pharmaceutical sector. Our pharmaceutical attorneys advise manufacturers, funds and institutions on transactions and disputes involving branded and generic pharmaceuticals, biotechnology equipment, clinical systems, nanotechnology, medical software and prescription drugs, drug delivery and drug packaging.
We have advised on a diverse range of mergers and acquisitions and other transactions.
The wider Curtis team includes experts in the field of healthcare compliance, as well as former medical doctors and lawyers with experience in pharmaceutical patent and regulatory (Hatch-Waxman) litigation in the U.S.
This has enabled Curtis to develop a range of experience in the pharmaceutical sector, ranging from healthcare issues to compliance and specialist intellectual property. Our healthcare attorneys have also advised on the development and financing of healthcare infrastructure projects such as hospitals in many countries, by way of PPI as well as traditional project finance and Islamic finance.
Intellectual Property Litigation
Commercial Disputes - Litigation
Legal 500 USA, 2019
Legal 500: USA M&A(Middle-Market) 2017
Legal 500 USA 2019